Scandion Oncology announces results from the next evaluable chemo-resistant colorectal cancer patient treated with SCO-101 and chemotherapy
Scandion Oncology A/S (“Scandion Oncology”) reports that the next evaluable colorectal cancer patient at the 8 weeks CT-scanning shows stable disease in the patients liver metastases, which are used to measure disease activity but a new metastatic lesion has appeared in the lung of the patient. According to the clinical protocol the patient will discontinue protocol treatment.
In the first cohort of chemotherapy resistant colorectal cancer patients treated with SCO-101 and chemotherapy (FOLFIRI) we now have evaluated treatment effects on tumor size in the first two patients. One patient has obtained stable disease, according to RECIST version 1.1 at 8 weeks after starting the treatment. The patient with new metastatic lesion in the lung will now discontinue protocol treatment although the liver metastases show stable disease.
The patients included have late stage metastatic colorectal cancer, for whom no additional treatment is available. All patients have previously had benefit with FOLFIRI (chemotherapy) treatment but subsequently, their cancer started to grow or showed new metastatic lesions despite the continued FOLFIRI treatment. The patients were then offered to be enrolled in the Scandion Oncology clinical phase II trial. The primary objective of the first part of the trial is to establish the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI. Moreover, this part also provides the first data on efficacy of SCO-101 when combined with FOLFIRI.
CEO Nils Brünner says “I am satisfied with the progress we have had in our first part of the clinical colorectal cancer study. Even with few patients, the results showing stable disease in the first patient and stable liver metastases but a new lesion in the next evaluable patient are still encouraging. We have many patients still to be included, and I am looking forward to follow these patients. Scandion Oncology is learning a lot from the first patients in the dose finding part of the study, information that is used to establish the recommended dose of SCO-101 and chemotherapy for future patients/trials. We are now adding additional patients to cohort 1 to learn even more about the interactions between SCO-101 and FOLFIRI chemotherapy. We have decided that the next news release will be when part 1 has been finalized”.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 20, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.
Scandion Oncology has finalized the first 12 patients in the CORIST study
Scandion Oncology A/S (“Scandion” or the “Company”) has completed the first 12 patient cohort in the ongoing dose-range finding part of the clinical phase II study with SCO-101 in combination with chemotherapy (FOLFIRI) in patients with drug resistant metastatic colorectal cancer. The Company has no...
Flaggningsmeddelande: Bolagets största aktieägare ökar till över 20%:s ägarandel i ObsteCare AB (publ)
Bolaget har informerats om att Peder Månsson har ökat sitt innehav i Bolaget över flaggningsgränsen 20 procent. Totalt innehav före transaktionen var 6073880 aktier motsvarande 19,53 procent av aktierna och rösterna i Bolaget. Efter transaktionen uppgår det totala innehavet till 63...
Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered
The Company has, based on a Board resolution from 6 May 2020, issued 516,262 new shares, as a debt conversion of SEK 455,860, equivalent to 516,262 shares, issued to Aalto Capital AB for services rendered to the Company. The new shares hold no special rights. The subscription was made a...
DBP International AB: VD kommenterar avyttringen av 377 000 aktier i DBP International AB via bolaget SI Studio AB
Affären genomfördes för att betala för ägar-omstruktureringen i SI-Studio. I resultatet ökade Igor Lokots ägande andel från ca 92.7% till mer än 99.5%. Igor Lokot via SI-Studio AB och privat är den största ägaren i DBP med 1 miljon A-aktier och nästan 9 miljoner B-aktier, motsvarande 23 procent av k...